Experts present research on osteoarthritis treated with Artneo^® complex

Clinical studies support the use of Artneo^® to significantly reduce pain and improve joint function in osteoarthritis^[1],^[2]. These studies were presented at the 7th Eurasian Congress of Rheumatologists LEAR 2024, as well as at the 8th International Congress of the Association of Rheumatologists-Orthopedists and the 4th All-Russian Scientific and Practical Conference Musculoskeletal Pain in Rheumatic Diseases held in September 2024.

About 7.6% of people globally have already been diagnosed with osteoarthritis^[3], and its incidence has increased by 132% in the last 30 years. In Russia, the number of patients with this diagnosis may reach 14-16 million people^[4]. Researchers predict that the incidence of osteoarthritis of knee joints will increase by 74.9%, hand joints by 48.6% and hip joints by 78.6% by 2050^[5].

Osteoarthritis can occur and develop depending on many factors, both hereditary and external^[6]. These factors include joint trauma, low activity level and unbalanced high-calorie diet, as well as comorbidities: diabetes mellitus, dyslipidemia, cardiovascular diseases.

Modern therapy has a problem given the limited therapeutic tools it uses to combat this disease. Most often patients with osteoarthritis are offered^[7] therapy with nonsteroidal anti-inflammatory drugs and chondroprotective agents. However, such therapy does not improve quality of life in most patients^[8].

Dr. Alekseeva has revealed several clinical studies confirming the positive effect native collagen type II has in relieving osteoarthritis symptoms. In a patient with osteoarthritis, the immune system perceives its own type II collagen, which is released during joint destruction, as a foreign substance, and therefore triggers a response against it, accompanied by inflammation. Undenatured type II collagen teaches the body not to respond with inflammation to its own collagen: it promotes the production of anti-inflammatory cytokines and reduces inflammation.

Artneo^® is an innovative 5-component complex with undenatured type II collagen, MSM, boswellic acids, vitamins C and D3 in its composition. This product helps to reduce discomfort, swelling, pain and stiffness, restores and maintains the functional state of joints and the spine.

Several studies support the positive results of Artneo^® application. In particular, a multicenter prospective, double-blind placebo-controlled randomized study in patients with stage II-III primary knee osteoarthritis involving 212 patients aged 40 to 75 years^[1] demonstrated significant reduction in pain severity and improved joint function.

An open-label randomized prospective study of Artneo^® compared to a combination of glucosamine hydrochloride and chondroitin sulfate (GC) involving 70 patients aged 40-75^[1] years confirmed a more significant clinical effect of Artneo^® vs. GC in patients with stage 1-3 gonarthrosis^[2]. The study showed a significant reduction of pain severity, stiffness, better joint function and a 61.2% reduction in the total WOMAC score after 6 months. Thus, Artneo^® can be recommended for use in the complex therapy of osteoarthritis, including in patients with limited use of nonsteroidal anti-inflammatory agents.

Experts believe that the evidence on efficacy and safety assessment they have compiled is the reason to include Artneo^® in methodological and clinical guidelines for gonarthrosis diagnosis, prevention and treatment^[9].